dr. halmos on the impact of egfr inhibitors on the treatment of lung cancer
Published 10 years ago • 198 plays • Length 1:25Download video MP4
Download video MP3
Similar videos
-
1:34
dr. halmos on the implications of the ipass study in lung cancer
-
1:24
dr. halmos on the implications of the ipass study in lung cancer
-
2:40
dr. halmos on met mutations in patients with nsclc
-
1:32
dr. hirsch discusses the role of next-generation egfr inhibitors
-
1:37
dr. yu on treatments for egfr-mutant lung cancer
-
0:59
dr. west on emerging changes in the field of egfr-mutant nsclc
-
8:30
third-generation egfr inhibitors in nsclc
-
2:02
evolutions in the treatment of egfr-mutated nsclc
-
9:30
egfr testing for nsclc
-
1:41
dr. husain on monitoring the emergence of t790m in lung cancer
-
1:29
dr. lynch on targeting egfr mutation subtypes in lung cancer
-
6:56
first-line therapy in the patient with egfr-mutant lung cancer
-
1:13
the impact of p53 mutation on survival in egfr-mutated nsclc patients
-
1:59
treatment options for egfr-positive lung cancer
-
6:25
managing egfr inhibitor associated skin toxicity
-
1:47
dr. scagliotti on mechanisms of resistance to egfr tkis
-
1:14
dr. david spigel discusses the evolving non-small cell lung cancer treatment landscape
-
1:00
dr. husain on the future of monitoring t790m in lung cancer
-
1:58
dr. bazhenova on sequencing beyond progression in egfr-mutant nsclc